Nasonex Bayer nasal spray treatment for allergic rhinitis (60 doses)

Dosage form Box x 300g
Specifications Mometasone Furoate

Ingredient

Thành phần cho 1 liều

Composition information	Content
Mometasone Furoate	50mcg

Uses

Indications

Nasonex 0.05%drug is indicated for adults, adolescents and children aged 2 to 11 years in the following cases:

Treatment of seasonal or year -round rhinitis.

In patients with a history of allergic rhinitis seasonal with average to severe symptoms, so preventive treatment with Nasonex Aqueous Nasal Spray from 2 to 4 weeks before starting the pollen season. Acute sinuses in patients> 12 years old without signs or symptoms of severe infections.

Pharmacy

In the study using antigen stimulants, Nasonex Aqueous Nasal Spray shows anti -inflammatory effects in both early and late response stage. This is shown by the decrease phenomenon (compared to the Placebo) that works histamine and eosin cells prefer EOSIN and decreased (compared to the original) Eosin, neutrophils and epithelial cell adhesion proteins.

In clinical research with nasal polyps, nasonex shows a significant improvement in related symptoms such as congestion and loss of smell compared to placebo.

In 2 clinical trials with 1954 patients over 12 years old, Nasonex nasal spray 0.05% 200 mcg, 2 times/day effectively controlling the symptoms of sinusitis significantly compared to the placebo during 15 days of treatment using the main symptomatic assessment method (pain/severe sensation/sensitivity of face pain, sinus pain, nose runny nose, congestion (P02683 P

The treatment group with Nasonex Aqueous Nasal Spray 200 mcg, 2 times/day with few patients is considered a failure with the place of placebo (P = 0.0074). Moreover, during the monitoring period after the treatment process, the number of patients recurring in Nasonex treatment group is lower and can be compared to the amoxicillin and placebo treatment team. The treatment time exceeds 15 days is not evaluated in patients with acute sinusitis.

pharmacokinetics

Mometason Furoat, when using nasal spray, bioavailable body

Before taking Nasonex Bayer nasal spray treatment for allergic rhinitis (60 doses)

How to use

After the Nasonex Aqueous Nasal Spray pump bait (usually 10 sprays until the mist is uniform), each spray is released about 100 mg of Mometason Furoat chemistry, containing Mometason Furoat Monohydrate, equivalent to 50 mcg toreton Furoat. If you do not use a spray within 14 days or longer, before the next use, you need to bait pump again (spray 2 spray until you see a foggy fog).

Shake Nasonex nasal spray thoroughly 0.05%before each use.

Dosage

Seasonal or year -round allergic rhinitis:

Adults (including the elderly) and teenagers: The usual proposal for prophylaxis and treatment are two sprays (50 mcg/spray) for each side of the nose, 1 time/day (total dose of 200 mcg). Once the symptoms have been controlled, the dose reduced to 1 spray for each nose (total dose of 100 mcg) can be effectively maintained.

If not controlled symptoms, it should be increased to the maximum daily dose of 4 sprays for each nose/day (total dose of 400 mcg). The dose should be reduced after control of symptoms. Clinical significant effects appear early after 12 hours of first dose.

Children from 2 to 11 years old: The normal dose is 1 spray (50 mcg/spray) for each nose, 1 time/day (total dose of 100 mcg). Adults should help children when taking medicine.

Nose polyps:

Adults (including the elderly) and teenagers 2 - 18 years old: The usual suggestion in nose polyps is 2 sprays (50 mcg/spray) for each side x 2 times/day (total dose of 400 mcg). Once the symptoms have been controlled well, the dose should be reduced to 2 sprays for each side of the nose, 1 time/day (total dose of 200 mcg).

Sinusitis:

Adults and teenagers> 12 years old: The usual proposal in sinus rhinitis is 2 sprays (50 mcg/spray) for each side x 2 times/day (total dose of 400 mcg). Ask your doctor if the symptom becomes worse during treatment.

Support treatment in acute sinusitis:

Adults (including the elderly) and teenagers> 12 years: The normal suggestion is 2 sprays (50 mcg/spray) each. Without good symptoms can increase up to 4 sprays (50 mcg/spray) for each side x 2 times/day (total dose of 800 mcg).

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose?

What to do when forgetting a dose? However, if close to the next dose, skip the forgotten dose and take Nasonex nasal spray 0.05% next time as planned.

Side Effects

When using Nasonex , you may experience unwanted effects (ADR).

Seasonal and year -round allergic rhinitis:

Local disadvantages related to treatment are reported in clinical studies in adults and adolescents including headaches (8%), nosebleeds (such as real bleeding, blood mucus mixed with blood, and bleeding spots) (8%), pharyngitis (4%), irritation of nose (2%), stimulating nose (2%), these effects are mainly observed. See with nasal corticosteroids. Nosebleeds often go away on their own and from mild to severe, appearing at a higher rate than Placebo (5%) but at a ratio of or lower than the corticosteroids in the nose in the control study (up to 15%). The ratio of other disadvantages is similar to Placebo.

In children, the proportion of adverse effects such as headache (3%), nosebleeds (6%), nose stimulation (2%) and sneezing (2%) are similar to placo.

Instant hypersensitivity reactions (such as bronchospasm, Difficulty ), but rarely, may appear after using Mometason Furoat monohydrate nose. Very rarely report on anaphylactic and angioed reactions.

Very rare reports to change the taste and smell.

Nose polyps:

In patients with nasal polyps, generally the occurrence of adverse manifestations is similar to the Placebo and similar to the disadvantage of observed disadvantage with allergic rhinitis.

Sinusitis:

In patients with acute sinusitis, generally the occurrence of adverse manifestations is similar to the Placebo and similar to the side effects observed with allergic rhinitis.

Support treatment in acute sinusitis:

In adults and young people using Nasonex Aqueous Nasal Spray such as supportive treatment during acute sinusitis, side effects related to treatment, appearing in the same proportion as Placebo, including headache (2%), pharyngitis (1%), nasal burning (1%) and stimulation of the nose (1%). Mild to severe nosebleeds and also appears with the comparison ratio with Placebo (5% compared to 4%).

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Nasonex drug contraindicated in the following cases:

Hypersensitivity to any component of Nasonex Aqueous Nasal Spray.

should not use Nasonex Aqueous Nasal Spray when there is an untreated bacterial infection in the nasal mucosa.

Because corticosteroids inhibit wound healing, do not use nasal corticosteroids for patients with nasal surgery or trauma until wound healing.

Precautions when using

after 12 months of treatment with Nasonex nose spray 0.05%, no evidence of nasal atrophy; In addition, Mometason Furoat tends to restore the nasal mucosa back to normal phenomenon. Like any other prolonged treatment, the patient used Nasonex Aqueous Nasal Spray for many months so it is checked for periodic changes that may appear in the nasal mucosa. If the fungal infection is localized in the nose or the pharyngeal, stop using Nasonex Aqueous Nasal Spray or may need appropriate treatment. Stimulating long nose can be an indication to stop using Nasonex Aqueous Nasal Spray.

Should use Nasonex Aqueous Nasal Spray cautious in patients with tuberculosis or respiratory tract, or fungal infection, bacterial infection, unactrured body virus or herpes simplex herpes.

There is no evidence to inhibit the hypothalamus - pituitary - adrenal gland (HPA) after prolonged treatment with Nasonex Aqueous Nasal Spray. However, careful monitoring of patients who switch from prolonged use of corticosteroids to the body to Nasonex Aqueous Nasal Spray. Stop using whole corticosteroids in these patients can cause adrenal insufficiency for months until the HPA shaft function recovers. Systemic corticosteroids should be reused if the patient shows signs of adrenal inhibitors and symptoms and should apply other appropriate treatments.

In a reference clinical study, there is no observation of a decrease in growth in children using Nasonex Aqueous Nasal Spray 100 mcg/day for 1 year.

Not safe and effective research of Nasonex Aqueous Nasal Spray in the treatment of nasal polyps in children and teenagers under 18 years old.

During the transition from the whole corticosteroid to Nasonex Aqueous Nasal Spray, some patients may manifest the symptoms of stopping the use of systemic corticosteroids (such as joint pain and/or muscle, fatigue and depression in the first stage) despite the reduction of symptoms in the nose and still need to continue Nasonex Aqueous Nasal Spray. This stage of conversion may appear existing allergies, such as allergic and eczema, which was previously covered by systemic corticosteroid treatment.

Patients who use strong corticosteroids inhibit immunosuppression should be warned when exposed to some infections (such as chicken pox, measles) and the importance of medical examination if exposed to the infection.

Very rare reporting or increased intraocular pressure after using corticosteroid spray inside the nose.

acute sinusitis. Patients should see a doctor immediately if signs or symptoms of severe infections (such as fever, pain and extend on one side/tooth or swelling of the face, eyes or area around the eyes, or symptoms worsens after a period of improvement). The safety and effectiveness of Nasonex Aqueous Nasal Spray in treating sinusitis symptoms in children under 12 years old.

The ability to drive and operate machinery

Not known whether Nasonex 0.05% nasal spray has the ability to drive and operate machinery.

Pregnancy

There is no appropriate research or good control in pregnant women.

As well as other corticosteroid preparations, Nasonex Aqueous Nasal Spray should only be used for pregnant women or at reproductive age when the benefits of treatment outstanding for mothers and fetuses.

Breastfeeding period

There is no appropriate research or good control in breastfeeding women.

As well as other corticosteroids using nasal sugars, Nasonex Aqueous Nasal Spray should be used for breastfeeding women when the treatment benefits are outstanding in the risk of emulsion.

Drug interaction

Nasonex Aqueous Nasal Spray used in combination with Loratadin does not affect the plasma concentration of Loratadin and its main metabolites. In these studies, the quantitative method with quantitative limit of 50 PG/mL does not predict the plasma toretason furoat concentration. Combined treatment is well tolerated.

Storage

Storage below 30 ° C. Avoid heat and no freezing.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.